Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III Study of Trafermin 0.01% Spray in Neuropathic Diabetic Foot Ulcer
2010-021014-33Phase 3Completed
- Sponsor
- Olympus
- Start
- Aug 2010
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in diabetic foot ulcer (DFU) and type 2 diabetes mellitus (T2DM) comparing Trafermin arm with Placebo arm (2 arms). Primary endpoint: Complete wound closure rate at 12 weeks. Started Aug 2010; status: completed.
02
Drugs
trafermin
03
Conditions
diabetic foot ulcer (DFU)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2010-021014-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-021014-33.